Profusa issued 201,120 common shares and 52,903.566 Series A Non‑Voting Convertible Preferred Shares , linking a Call Option on G3 Vision Labs that requires at least $30 million of financing. The deal could add an estimated $111 million of diagnostics Revenue , expanding the company’s market footprint and potential upside for shareholders.

Key Highlights

  • Profusa provided 201,120 common shares and 52,903.566 Series A Preferred shares as consideration under the G3 option agreement.
  • The option obliges Profusa to secure aggregate gross proceeds of at least $30 million before it can be exercised.
  • G3 Vision Labs reported estimated 2025 net revenues of approximately $111 million, forming the financial basis for the potential Acquisition .

The transaction also ties the potential addition of G3’s estimated $111 million of 2025 net revenues to Profusa’s Balance Sheet , offering investors a clear pathway to expanded diagnostic services.

Option Mechanics and Consideration

The agreement grants Profusa a call option to purchase 100 % of the Equity securities held by the sellers in G3 Vision Labs, which itself owns all of Med Screen Laboratories, Dominion Diagnostics, and Acutis Diagnostics. In exchange for the option, Profusa transferred 201,120 common shares and 52,903.566 Series A Preferred shares to the sellers. This structure aligns the sellers’ upside with the successful financing and integration of the target businesses.

Financing Condition and Timeline

The key trigger for exercising the option is the attainment of aggregate gross proceeds of at least $30 million, either to Profusa or directly to G3. This financing must be consummated or secured through binding commitments before the option can be acted upon. The option remains exercisable until 90 days after G3 delivers audited financial statements for its 2024 and 2025 fiscal years, with a final expiration on September 2, 2026.

Upon exercise, the closing must occur within 75 days, after which Profusa will file a registration statement to facilitate resale of the newly Issued Shares . The tight timeline pressures both parties to align financing and regulatory steps promptly.

Strategic Rationale and Market Impact

By securing the option, Profusa positions itself to enter the diagnostics market with a ready‑made platform, diversifying its digital health portfolio beyond biosensor technology. The financing prerequisite underscores the need for Capital to refinance existing G3 indebtedness and fund integration, a move that could enhance Cash Flow stability for the combined entity. Investors observing the deal should note the potential dilution from the Preferred conversion, balanced against the revenue uplift from a fully integrated diagnostics Business .

Next Catalyst and Investor Focus

The immediate focus turns to Profusa’s ability to lock in the required $30 million financing before the September 2, 2026 deadline, a milestone that will determine whether the option proceeds to execution. Market Participants will monitor upcoming financing round disclosures and any Shareholder meeting outcomes related to the Preferred Stock conversion proposal, as these events will directly influence the valuation and Liquidity prospects of the combined enterprise.

Analysis based on the Form 8-K filed 31 July 2026; figures verified against the filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.